There was negative correlation of sPD-L1 serum concentration and CD8+ tumor expression in subgroups of Durvalumab-treated mice that carried both primary and relapsed NMIBC of GATA 3 and KRT 5/6 expressed subtypes; in respective control subgroups, the indicators did not correlate. Here, CD8A is linked to neoplasm.